Condition: Relapsed or Refractory Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) · Sponsor: Kartos Therapeutics, Inc.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive monotherapy (KRT-232 alone) or combination therapy (KRT-232 with LDAC or KRT-232 with Decitabine).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Chicago | Chicago, Illinois, United States | — |
| University of Maryland Medical Center | Baltimore, Maryland, United States | — |
| Mount Sinai | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Weill Cornell | New York, New York, United States | — |
| The Ohio State University | Columbus, Ohio, United States | — |
| Oregon Health and Science University | Portland, Oregon, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Monash Health | Clayton, Australia | — |
| St. George Hospital | Kogarah, Australia | — |
| Royal Perth Hospital | Perth, Australia | — |
| Calvary Mater Newcastle Hospital | Waratah, Australia | — |
+ 47 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04113616